Biological functions of vasoactive intestinal peptide (VIP) in respiratory system and potential clinical application

被引:0
|
作者
Onoue, Satomi [1 ]
Misaka, Shingen
Yajima, Takehiko
Yamada, Shizuo
机构
[1] Univ Shizuoka, Sch Pharmaceut Sci, Dept Pharmacokinet & Pharmacodynam, Shizuoka, Japan
[2] Toho Univ, Fac Pharmaceut Sci, Dept Analyt Chem, Funabashi, Chiba, Japan
来源
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN | 2007年 / 127卷
关键词
VIP; COPD; caspase; cigarette smoke; matrix metalloprotease; CIGARETTE-SMOKE; POLYPEPTIDE; RECEPTORS; ANALOG;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In a respiratory system, VIP acts as neurotransmitter or neuromodulator of the inhibitory non-adrenergic and non-cholinergic nervous system and influences many aspects of pulmonary biology. A clinical application of VIP is believed to offer potential benefits in the treatment of chronic inflammatory lung diseases, because of its attractive biological functions including anti-inflammation and bronchodilation. In this investigation, development of efficacious VIP derivatives and drug delivery systems was attempted for the potential application of VIPs for treatment of asthma/chronic obstructive pulmonary disease (COPD). VIP and derivatives were chemically synthesized, and their solution structures were evaluated by circular dichroic and NMR spectral analyses. In addition, several biological functions of VIPs, including stimulation of protein kinases, receptor binding, relaxant effects on smooth muscle, protective effects on cigarette smoke-induced apoptotic cell death, were also investigated. On the basis of chemical modification studies, potent VIP receptor agonists, including [R (15,20,21), L (17)]-VIP-GRR (IK312532) and [R (15,20,21), L (17), A (24,25), des-N-28]-VIP-GRR (IK312548), were successfully developed. They showed long-lasting bronchodilation and anti-apoptotic effects via deactivation of caspase-3 and matrix metalloprotease.
引用
收藏
页码:207 / 211
页数:5
相关论文
共 50 条
  • [21] Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats
    Dufes, C
    Olivier, JC
    Gaillard, F
    Gaillard, A
    Couet, W
    Muller, JM
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 255 (1-2) : 87 - 97
  • [22] Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: Anti-inflammatory effect in experimental asthmatic rats
    Misaka, Shingen
    Aoki, Yosuke
    Karaki, Shin-ichiro
    Kuwahara, Atsukazu
    Mizumoto, Takahiro
    Onoue, Satomi
    Yamada, Shizuo
    PEPTIDES, 2010, 31 (01) : 72 - 78
  • [23] Vasoactive intestinal peptide and the mammalian circadian system
    Vosko, Andrew M.
    Schroeder, Analyne
    Loh, Dawn H.
    Colwell, Christopher S.
    GENERAL AND COMPARATIVE ENDOCRINOLOGY, 2007, 152 (2-3) : 165 - 175
  • [24] Therapeutic Potential of Vasoactive Intestinal Peptide and its Derivative Stearyl-Norleucine-VIP in Inflammation-Induced Osteolysis
    Eger, Michal
    Liron, Tamar
    Hiram-Bab, Sahar
    Awida, Zamzam
    Giladi, Eliezer
    Dangoor, David
    Fridkin, Mati
    Kohavi, David
    Gozes, Illana
    Gabet, Yankel
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [25] Parasympathetic vasoactive intestinal peptide (VIP): a likely contributor to clozapine-induced sialorrhoea
    Ekstrom, J.
    Godoy, T.
    Loy, F.
    Riva, A.
    ORAL DISEASES, 2014, 20 (03) : e90 - e96
  • [26] Vasoactive intestinal peptide (VIP)-mediated expression and function of steroidogenic acute regulatory protein (StAR) in granulosa cells
    Kowalewski, Mariusz P.
    Dyson, Matthew T.
    Boos, Alois
    Stocco, Douglas M.
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2010, 328 (1-2) : 93 - 103
  • [27] Vasoactive intestinal peptide (VIP) conducts the neuronal activity during absence seizures: GABA seems to be the main mediator of VIP
    Korkmaz, Orhan Tansel
    Arkan, Sertan
    Oncu-Kaya, Elif Mine
    Ates, Nurbay
    Tuncel, Nese
    NEUROSCIENCE LETTERS, 2021, 765
  • [28] Site-directed mutagenesis of vasoactive intestinal peptide (VIP) receptor subtypes VIP1 and VIP2. Difference in their structure-function relationship.
    Nicole, P
    Du, K
    Couvineau, A
    Laburthe, M
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1997, 21 (05): : 365 - 369
  • [29] INVOLVEMENT OF VASOACTIVE-INTESTINAL-PEPTIDE (VIP) AS A HUMORAL MEDIATOR OF PENILE ERECTILE FUNCTION IN THE DOG
    AOKI, H
    MATSUZAKA, J
    YEH, KH
    SATO, F
    FUJIOKA, T
    KUBO, T
    OHHORI, T
    YASUDA, N
    JOURNAL OF ANDROLOGY, 1994, 15 (02): : 174 - 182
  • [30] Stapled Vasoactive Intestinal Peptide (VIP) Derivatives Improve VPAC2 Agonism and Glucose-Dependent Insulin Secretion
    Giordanetto, Fabrizio
    Revell, Jefferson D.
    Knerr, Laurent
    Hostettler, Marie
    Paunovic, Amalia
    Priest, Claire
    Janefeldt, Annika
    Gill, Adrian
    ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (12): : 1163 - 1168